---
document_datetime: 2025-11-23 08:02:47
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/topotecan-eagle.html
document_name: topotecan-eagle.html
version: success
processing_time: 0.1204191
conversion_datetime: 2025-12-29 23:35:00.879045
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Topotecan Eagle

[RSS](/en/individual-human-medicine.xml/65721)

##### Withdrawn

This medicine's authorisation has been withdrawn

topotecan

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 2 October 2014, the European Commission withdrew the marketing authorisation for Topotecan Eagle (topotecan) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Eagle Laboratories Ltd, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Topotecan Eagle was granted marketing authorisation in the EU on 22 December 2011 for the treatment of patients with relapsed small cell lung cancer when re-treatment with the first-line regimen is not considered appropriate. It was also approved for the treatment of women with cancer of the cervix in combination with cisplatin when the cancer has come back after radiotherapy, or when the disease is at an advanced stage (stage IVB: the cancer has spread beyond the cervix). The marketing authorisation was initially valid for a 5-year period.

Topotecan Eagle is a 'hybrid generic medicine' of Hycamtin. There are other generic medicinal products of Hycamtin authorised and marketed in the EU.

The European Public Assessment Report (EPAR) for Topotecan Eagle is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

Topotecan Eagle : EPAR - Summary for the public

Reference Number: EMEA/H/C/002261

English (EN) (496.66 KB - PDF)

**First published:** 12/01/2012

**Last updated:** 14/11/2014

[View](/en/documents/overview/topotecan-eagle-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-954)

български (BG) (1.03 MB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/bg/documents/overview/topotecan-eagle-epar-summary-public_bg.pdf)

español (ES) (975.4 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/es/documents/overview/topotecan-eagle-epar-summary-public_es.pdf)

čeština (CS) (1022.52 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/cs/documents/overview/topotecan-eagle-epar-summary-public_cs.pdf)

dansk (DA) (974.3 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/da/documents/overview/topotecan-eagle-epar-summary-public_da.pdf)

Deutsch (DE) (959.98 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/de/documents/overview/topotecan-eagle-epar-summary-public_de.pdf)

eesti keel (ET) (953.85 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/et/documents/overview/topotecan-eagle-epar-summary-public_et.pdf)

ελληνικά (EL) (1.1 MB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/el/documents/overview/topotecan-eagle-epar-summary-public_el.pdf)

français (FR) (960.04 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/fr/documents/overview/topotecan-eagle-epar-summary-public_fr.pdf)

italiano (IT) (960.03 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/it/documents/overview/topotecan-eagle-epar-summary-public_it.pdf)

latviešu valoda (LV) (1 MB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/lv/documents/overview/topotecan-eagle-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (983.96 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/lt/documents/overview/topotecan-eagle-epar-summary-public_lt.pdf)

magyar (HU) (1016.43 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/hu/documents/overview/topotecan-eagle-epar-summary-public_hu.pdf)

Malti (MT) (1023.18 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/mt/documents/overview/topotecan-eagle-epar-summary-public_mt.pdf)

Nederlands (NL) (959.63 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/nl/documents/overview/topotecan-eagle-epar-summary-public_nl.pdf)

polski (PL) (1.06 MB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/pl/documents/overview/topotecan-eagle-epar-summary-public_pl.pdf)

português (PT) (958.77 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/pt/documents/overview/topotecan-eagle-epar-summary-public_pt.pdf)

română (RO) (983.57 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/ro/documents/overview/topotecan-eagle-epar-summary-public_ro.pdf)

slovenčina (SK) (1020.56 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/sk/documents/overview/topotecan-eagle-epar-summary-public_sk.pdf)

slovenščina (SL) (1016.61 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/sl/documents/overview/topotecan-eagle-epar-summary-public_sl.pdf)

Suomi (FI) (957.81 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/fi/documents/overview/topotecan-eagle-epar-summary-public_fi.pdf)

svenska (SV) (958.13 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/sv/documents/overview/topotecan-eagle-epar-summary-public_sv.pdf)

## Product information

Topotecan Eagle : EPAR - Product Information

English (EN) (849.35 KB - PDF)

**First published:** 12/01/2012

**Last updated:** 14/11/2014

[View](/en/documents/product-information/topotecan-eagle-epar-product-information_en.pdf)

[Other languages (23)](#file-language-dropdown-58)

български (BG) (3.13 MB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/bg/documents/product-information/topotecan-eagle-epar-product-information_bg.pdf)

español (ES) (1.56 MB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/es/documents/product-information/topotecan-eagle-epar-product-information_es.pdf)

čeština (CS) (2.43 MB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/cs/documents/product-information/topotecan-eagle-epar-product-information_cs.pdf)

dansk (DA) (1.52 MB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/da/documents/product-information/topotecan-eagle-epar-product-information_da.pdf)

Deutsch (DE) (1.58 MB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/de/documents/product-information/topotecan-eagle-epar-product-information_de.pdf)

eesti keel (ET) (1.54 MB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/et/documents/product-information/topotecan-eagle-epar-product-information_et.pdf)

ελληνικά (EL) (3.18 MB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/el/documents/product-information/topotecan-eagle-epar-product-information_el.pdf)

français (FR) (1.55 MB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/fr/documents/product-information/topotecan-eagle-epar-product-information_fr.pdf)

íslenska (IS) (1.62 MB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/is/documents/product-information/topotecan-eagle-epar-product-information_is.pdf)

italiano (IT) (1.54 MB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/it/documents/product-information/topotecan-eagle-epar-product-information_it.pdf)

latviešu valoda (LV) (2.58 MB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/lv/documents/product-information/topotecan-eagle-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.7 MB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/lt/documents/product-information/topotecan-eagle-epar-product-information_lt.pdf)

magyar (HU) (2.44 MB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/hu/documents/product-information/topotecan-eagle-epar-product-information_hu.pdf)

Malti (MT) (2.56 MB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/mt/documents/product-information/topotecan-eagle-epar-product-information_mt.pdf)

Nederlands (NL) (1.55 MB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/nl/documents/product-information/topotecan-eagle-epar-product-information_nl.pdf)

norsk (NO) (1.69 MB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/no/documents/product-information/topotecan-eagle-epar-product-information_no.pdf)

polski (PL) (2.58 MB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/pl/documents/product-information/topotecan-eagle-epar-product-information_pl.pdf)

português (PT) (1.56 MB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/pt/documents/product-information/topotecan-eagle-epar-product-information_pt.pdf)

română (RO) (1.76 MB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/ro/documents/product-information/topotecan-eagle-epar-product-information_ro.pdf)

slovenčina (SK) (2.35 MB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/sk/documents/product-information/topotecan-eagle-epar-product-information_sk.pdf)

slovenščina (SL) (2.35 MB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/sl/documents/product-information/topotecan-eagle-epar-product-information_sl.pdf)

Suomi (FI) (1.5 MB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/fi/documents/product-information/topotecan-eagle-epar-product-information_fi.pdf)

svenska (SV) (1.52 MB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/sv/documents/product-information/topotecan-eagle-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0001 02/10/2014

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Topotecan Eagle : EPAR - All Authorised presentations

English (EN) (456.85 KB - PDF)

**First published:** 12/01/2012

**Last updated:** 14/11/2014

[View](/en/documents/all-authorised-presentations/topotecan-eagle-epar-all-authorised-presentations_en.pdf)

[Other languages (23)](#file-language-dropdown-388)

български (BG) (960.08 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/bg/documents/all-authorised-presentations/topotecan-eagle-epar-all-authorised-presentations_bg.pdf)

español (ES) (910.24 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/es/documents/all-authorised-presentations/topotecan-eagle-epar-all-authorised-presentations_es.pdf)

čeština (CS) (949.97 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/cs/documents/all-authorised-presentations/topotecan-eagle-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (910.25 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/da/documents/all-authorised-presentations/topotecan-eagle-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (910.24 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/de/documents/all-authorised-presentations/topotecan-eagle-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (910.01 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/et/documents/all-authorised-presentations/topotecan-eagle-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (958.92 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/el/documents/all-authorised-presentations/topotecan-eagle-epar-all-authorised-presentations_el.pdf)

français (FR) (910.13 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/fr/documents/all-authorised-presentations/topotecan-eagle-epar-all-authorised-presentations_fr.pdf)

íslenska (IS) (911.08 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/is/documents/all-authorised-presentations/topotecan-eagle-epar-all-authorised-presentations_is.pdf)

italiano (IT) (910.24 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/it/documents/all-authorised-presentations/topotecan-eagle-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (951.5 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/lv/documents/all-authorised-presentations/topotecan-eagle-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (937.77 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/lt/documents/all-authorised-presentations/topotecan-eagle-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (935.54 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/hu/documents/all-authorised-presentations/topotecan-eagle-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (960.23 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/mt/documents/all-authorised-presentations/topotecan-eagle-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (910.18 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/nl/documents/all-authorised-presentations/topotecan-eagle-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (910.87 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/no/documents/all-authorised-presentations/topotecan-eagle-epar-all-authorised-presentations_no.pdf)

polski (PL) (950.49 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/pl/documents/all-authorised-presentations/topotecan-eagle-epar-all-authorised-presentations_pl.pdf)

português (PT) (910.27 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/pt/documents/all-authorised-presentations/topotecan-eagle-epar-all-authorised-presentations_pt.pdf)

română (RO) (937.01 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/ro/documents/all-authorised-presentations/topotecan-eagle-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (950.23 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/sk/documents/all-authorised-presentations/topotecan-eagle-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (922.27 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/sl/documents/all-authorised-presentations/topotecan-eagle-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (909.94 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/fi/documents/all-authorised-presentations/topotecan-eagle-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (910.36 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/sv/documents/all-authorised-presentations/topotecan-eagle-epar-all-authorised-presentations_sv.pdf)

Topotecan Eagle : EPAR - Conditions imposed on member states for safe and effective use

English (EN) (465.44 KB - PDF)

**First published:** 12/01/2012

**Last updated:** 14/11/2014

[View](/en/documents/conditions-member-states/topotecan-eagle-epar-conditions-imposed-member-states-safe-and-effective-use_en.pdf)

[Other languages (23)](#file-language-dropdown-192)

български (BG) (992.09 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/bg/documents/conditions-member-states/topotecan-eagle-epar-conditions-imposed-member-states-safe-and-effective-use_bg.pdf)

español (ES) (979.7 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/es/documents/conditions-member-states/topotecan-eagle-epar-conditions-imposed-member-states-safe-and-effective-use_es.pdf)

čeština (CS) (972.41 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/cs/documents/conditions-member-states/topotecan-eagle-epar-conditions-imposed-member-states-safe-and-effective-use_cs.pdf)

dansk (DA) (979.72 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/da/documents/conditions-member-states/topotecan-eagle-epar-conditions-imposed-member-states-safe-and-effective-use_da.pdf)

Deutsch (DE) (979.11 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/de/documents/conditions-member-states/topotecan-eagle-epar-conditions-imposed-member-states-safe-and-effective-use_de.pdf)

eesti keel (ET) (919.17 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/et/documents/conditions-member-states/topotecan-eagle-epar-conditions-imposed-member-states-safe-and-effective-use_et.pdf)

ελληνικά (EL) (992.33 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/el/documents/conditions-member-states/topotecan-eagle-epar-conditions-imposed-member-states-safe-and-effective-use_el.pdf)

français (FR) (979.85 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/fr/documents/conditions-member-states/topotecan-eagle-epar-conditions-imposed-member-states-safe-and-effective-use_fr.pdf)

íslenska (IS) (919.96 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/is/documents/conditions-member-states/topotecan-eagle-epar-conditions-imposed-member-states-safe-and-effective-use_is.pdf)

italiano (IT) (979.88 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/it/documents/conditions-member-states/topotecan-eagle-epar-conditions-imposed-member-states-safe-and-effective-use_it.pdf)

latviešu valoda (LV) (977.5 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/lv/documents/conditions-member-states/topotecan-eagle-epar-conditions-imposed-member-states-safe-and-effective-use_lv.pdf)

lietuvių kalba (LT) (1008.98 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/lt/documents/conditions-member-states/topotecan-eagle-epar-conditions-imposed-member-states-safe-and-effective-use_lt.pdf)

magyar (HU) (959.18 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/hu/documents/conditions-member-states/topotecan-eagle-epar-conditions-imposed-member-states-safe-and-effective-use_hu.pdf)

Malti (MT) (1019.87 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/mt/documents/conditions-member-states/topotecan-eagle-epar-conditions-imposed-member-states-safe-and-effective-use_mt.pdf)

Nederlands (NL) (920.11 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/nl/documents/conditions-member-states/topotecan-eagle-epar-conditions-imposed-member-states-safe-and-effective-use_nl.pdf)

norsk (NO) (919.57 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/no/documents/conditions-member-states/topotecan-eagle-epar-conditions-imposed-member-states-safe-and-effective-use_no.pdf)

polski (PL) (1.01 MB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/pl/documents/conditions-member-states/topotecan-eagle-epar-conditions-imposed-member-states-safe-and-effective-use_pl.pdf)

português (PT) (979.34 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/pt/documents/conditions-member-states/topotecan-eagle-epar-conditions-imposed-member-states-safe-and-effective-use_pt.pdf)

română (RO) (951.15 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/ro/documents/conditions-member-states/topotecan-eagle-epar-conditions-imposed-member-states-safe-and-effective-use_ro.pdf)

slovenčina (SK) (1.01 MB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/sk/documents/conditions-member-states/topotecan-eagle-epar-conditions-imposed-member-states-safe-and-effective-use_sk.pdf)

slovenščina (SL) (970.3 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/sl/documents/conditions-member-states/topotecan-eagle-epar-conditions-imposed-member-states-safe-and-effective-use_sl.pdf)

Suomi (FI) (919.49 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/fi/documents/conditions-member-states/topotecan-eagle-epar-conditions-imposed-member-states-safe-and-effective-use_fi.pdf)

svenska (SV) (979.53 KB - PDF)

**First published:**

12/01/2012

**Last updated:**

14/11/2014

[View](/sv/documents/conditions-member-states/topotecan-eagle-epar-conditions-imposed-member-states-safe-and-effective-use_sv.pdf)

## Product details

Name of medicine Topotecan Eagle Active substance topotecan hydrochloride International non-proprietary name (INN) or common name topotecan Therapeutic area (MeSH)

- Carcinoma
- Small Cell Lung Carcinoma

Anatomical therapeutic chemical (ATC) code L01CE01

### Pharmacotherapeutic group

Antineoplastic and immunomodulating agents

### Therapeutic indication

Topotecan monotherapy is indicated for the treatment of patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate.

Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB disease. Patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination.

## Authorisation details

EMA product number EMEA/H/C/002261

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Eagle Laboratories Ltd.

Eagle Laboratories Ltd.

Marketing authorisation issued 22/12/2011 Withdrawal of marketing authorisation 02/10/2014 Revision 2

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Topotecan Eagle : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (505.71 KB - PDF)

**First published:** 10/11/2014

**Last updated:** 14/11/2014

[View](/en/documents/procedural-steps-after/topotecan-eagle-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Topotecan Eagle : EPAR - Public assessment report

Adopted

Reference Number: EMA/1352/2012

English (EN) (686.15 KB - PDF)

**First published:** 12/01/2012

**Last updated:** 14/11/2014

[View](/en/documents/assessment-report/topotecan-eagle-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Topotecan Eagle

Adopted

Reference Number: EMA/CHMP/795162/2011

English (EN) (511.9 KB - PDF)

**First published:** 21/10/2011

**Last updated:** 14/11/2014

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-topotecan-eagle_en.pdf)

**This page was last updated on** 14/11/2014

## Share this page

[Back to top](#main-content)